IRIS
DI GIACOMO, ANNA MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.605
EU - Europa 7.729
AS - Asia 6.164
SA - Sud America 1.279
Continente sconosciuto - Info sul continente non disponibili 629
AF - Africa 330
OC - Oceania 16
Totale 26.752
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.334
IT - Italia 2.368
SG - Singapore 2.318
RU - Federazione Russa 1.855
CN - Cina 1.504
BR - Brasile 1.040
IE - Irlanda 981
VN - Vietnam 780
GB - Regno Unito 695
HK - Hong Kong 520
FR - Francia 422
DE - Germania 335
SE - Svezia 286
BD - Bangladesh 247
KR - Corea 243
ZA - Sudafrica 219
UA - Ucraina 187
FI - Finlandia 179
IN - India 155
NL - Olanda 122
CA - Canada 114
ES - Italia 98
AR - Argentina 88
MX - Messico 82
EC - Ecuador 49
AT - Austria 42
IQ - Iraq 42
PL - Polonia 39
ID - Indonesia 37
JP - Giappone 37
KE - Kenya 35
TR - Turchia 33
CO - Colombia 24
SA - Arabia Saudita 24
AZ - Azerbaigian 18
PK - Pakistan 18
VE - Venezuela 18
AE - Emirati Arabi Uniti 17
CL - Cile 17
IR - Iran 16
JM - Giamaica 16
PY - Paraguay 15
UZ - Uzbekistan 15
AL - Albania 14
AU - Australia 14
JO - Giordania 14
MY - Malesia 14
PH - Filippine 14
CH - Svizzera 13
CR - Costa Rica 13
MA - Marocco 13
NP - Nepal 13
PE - Perù 13
BE - Belgio 12
LT - Lituania 11
NG - Nigeria 11
DZ - Algeria 10
EG - Egitto 9
KG - Kirghizistan 9
KZ - Kazakistan 9
LB - Libano 9
TN - Tunisia 8
BG - Bulgaria 7
BH - Bahrain 7
BO - Bolivia 7
EE - Estonia 7
HN - Honduras 7
IL - Israele 7
OM - Oman 7
TH - Thailandia 7
CZ - Repubblica Ceca 6
ET - Etiopia 6
NO - Norvegia 6
PT - Portogallo 6
UY - Uruguay 6
BY - Bielorussia 5
DK - Danimarca 5
DO - Repubblica Dominicana 5
SV - El Salvador 5
GT - Guatemala 4
MD - Moldavia 4
NI - Nicaragua 4
PA - Panama 4
SK - Slovacchia (Repubblica Slovacca) 4
TT - Trinidad e Tobago 4
AM - Armenia 3
AO - Angola 3
BA - Bosnia-Erzegovina 3
BB - Barbados 3
CI - Costa d'Avorio 3
GR - Grecia 3
HU - Ungheria 3
KH - Cambogia 3
LK - Sri Lanka 3
LV - Lettonia 3
RO - Romania 3
SC - Seychelles 3
SY - Repubblica araba siriana 3
BN - Brunei Darussalam 2
BS - Bahamas 2
Totale 26.080
Salva come PNG Salva come JPEG
Città #
Dallas 1.552
Singapore 1.315
Dublin 975
Fairfield 817
Ashburn 797
San Jose 762
Milan 686
Santa Clara 588
Moscow 520
Hong Kong 495
Southend 453
Council Bluffs 409
Woodbridge 400
Hefei 380
Beijing 378
Seattle 350
Houston 326
Cambridge 299
Wilmington 295
Siena 268
Ho Chi Minh City 249
Rome 233
Seoul 232
Johannesburg 198
Lauterbourg 183
Los Angeles 177
Princeton 172
Jacksonville 164
The Dalles 163
New York 155
Hanoi 137
Ann Arbor 134
Florence 134
Chandler 117
Helsinki 113
Dong Ket 101
Shanghai 89
San Mateo 84
São Paulo 81
Amsterdam 67
Dearborn 66
Chicago 65
Buffalo 64
Columbus 61
Figino 54
Málaga 54
Bengaluru 51
Redondo Beach 51
Nuremberg 50
San Diego 47
London 46
Lappeenranta 43
Munich 42
Naples 41
Phoenix 41
Orem 39
Brooklyn 38
Denver 37
Frankfurt am Main 37
Rio de Janeiro 36
Montreal 34
Boardman 32
Turin 32
Haiphong 31
San Francisco 31
Bologna 30
Stockholm 30
Tokyo 30
Warsaw 30
Guangzhou 27
Mexico City 27
Nanjing 27
Toronto 27
Vienna 27
Chennai 26
Atlanta 24
Da Nang 24
Manchester 22
Belo Horizonte 21
Modena 21
Portsmouth 21
Guayaquil 20
Bari 19
Palermo 19
Brasília 18
Perugia 18
Borgo San Lorenzo 17
Boston 17
Cascina 17
Düsseldorf 17
Fremont 17
Poplar 17
Baku 16
Ninh Bình 15
Sesto Fiorentino 15
Tianjin 15
Turku 15
Charlotte 14
Curitiba 14
Dhaka 14
Totale 16.899
Salva come PNG Salva come JPEG
Nome #
Neurological adverse events of ICI therapy: A ten-year comprehensive management from a multidisciplinary team 516
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) 364
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme 340
Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: Results of a phase II study 333
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy 282
Immunomodulatory properties of DNA hypomethylating agents: Selecting the optimal epigenetic partner for cancer immunotherapy 273
Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial 271
Circulating levels of PD-L1 in mesothelioma patients from the NIBIT-MESO-1 study: Correlation with survival 263
A Multidisciplinary Approach to Improve the Management of Immune-Checkpoint Inhibitor-Related Pneumonitis 259
Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy 257
Biomolecular Predictors of Recurrence Patterns and Survival in IDH-Wild-Type Glioblastoma: A Retrospective Analysis of Patients Treated with Radiotherapy and Temozolomide 248
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme 247
Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches 244
Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/ mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study 243
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. 241
Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial 241
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial 239
Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab 238
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation 238
Back to simplicity: A four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients 232
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases 227
“Cancer Bio-Immunotherapy in Siena”: Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8–10, 2015 218
Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models 216
Association between Immune-Related Adverse Events and Recurrence-Free Survival among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial 215
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study 213
The italian experience on the feasibility and safety of ipilmumab therapy in pretracted metastatic melanoma patients 212
Ipilmumab in the daily practice: feasibility, safety, efficacy and long term follow-up in heavily pretreated metastatic melanoma patients 210
“Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013 208
Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients 204
Epigenetic immune remodeling of mesothelioma cells: A new strategy to improve the efficacy of immunotherapy 204
Brief Communication PD1-related Nephrotoxicity: Optimizing Its Clinical Management Through Histopathologic Features 203
A novel microRNA signature for the detection of melanoma by liquid biopsy 201
Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy 199
Rational Use of Monoclonal Antibodies as Therapeutic Treatment in an Oncologic Patient with Long COVID 198
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial 198
Ipilimumab in the common daily practice: feasibility, safety, efficacy and long-term follow-up in heavily pretreated metastatic melanoma patients 198
Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial 197
Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications 193
Immunotherapy targeting immune check-point(s) in brain metastases 189
Perspectives on the role of “-Omics” in predicting response to immunotherapy 188
A Phase II Study Combining Ipilimumab and Fotemustine in Patients With Metastatic Melanoma - the NIBIT-M1 Trial 187
Clinical Efficacy of the Anti-Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Monoclonal Antibody Ipilimumab in Pretreated Metastatic Uveal Melanoma Patients 186
Predictors of responses to immune checkpoint blockade in advanced melanoma 185
Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy 182
Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab 180
SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines 177
Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab 176
Molecular pathways: At the crossroads of cancer epigenetics and immunotherapy 174
Successful Targeting of CTLA-4 in a Melanoma Clinical Case: A Long-Term “One Stop Therapeutic Shop” 172
A phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: the NIBIT-M4 Study. 172
The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications 170
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian network for tumor biotherapy (NIBIT)-M1 phase II study 170
Primary hepatic epithelioid hemangioendothelioma progressively responsive to interferon-alpha: is there room for novel anti-angiogenetic treatments? 167
Ipilimumab in the common daily practice: Feasibility, safety, and efficacy in heavily pretreated metastatic melanoma patients 166
Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012 165
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238 164
The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role? 164
Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile 162
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial 162
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria 160
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915) 159
Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients 159
Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma 158
Challenges in lung cancer therapy during the COVID-19 pandemic 158
A novel method for monitoring response to chemotherapy based on the detection of circulating cancer cells: A case report 158
Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications 157
Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond 157
Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma 157
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis 156
Immunotherapy in melanoma: Can we predict response to treatment with circulating biomarkers? 155
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial 153
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases 153
Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: Comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells 153
Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial 151
Serum lactate dehydrogenase as a prognostic marker for treatment response in IDH wild-type glioblastoma patients undergoing stupp protocol 151
Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients 150
Long-term follow-up of a papillary tumor of the pineal region: addendum to a case report 150
Correction to: Predictive value of perilesional edema volume in melanoma brain metastasis response to stereotactic radiosurgery (Journal of Neuro-Oncology, (2024), 10.1007/s11060-024-04818-9) 148
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial 148
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study 148
Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era 148
Mutational concordance between primary and metastatic melanoma: A next-generation sequencing approach 147
Ipilmumab in pretreated metastatic uveal melanoma patiens; safety and clinical efficacy 145
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial 144
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial 143
Epigenetics meets immune checkpoints 143
Survival Outcomes in Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma Treated with Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial 143
Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy 143
Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma 142
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma 142
Dietary compounds and cutaneous malignant melanoma: Recent advances from a biological perspective 141
Nivolumab plus ipilimumab in melanoma brain metastases 141
Safety and immunobiological activity of guadecitabine sequenced with ipilimumab in metastatic melanoma patients: The phase Ib NIBIT-M4 study 141
The Italian experience on the feasibility and safety of ipilimumab therapy in pretreated metastatic melanoma patients 138
Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma 137
Predictive value of perilesional edema volume in melanoma brain metastasis response to stereotactic radiosurgery 137
Can epigenetics have a clinical impact in the treatment of melanoma? 136
Effects of molecular heterogeneity on survival of patients with BRAFV600-mutated melanoma treated with vemurafenib with or without cobimetinib in the coBRIM study 135
From Co-Stimulation to Co-Inhibition: A Continuum of Immunotherapy Care Toward Long-Term Survival in Melanoma 132
Adjuvant nivolumab for stage III/IV melanoma: Evaluation of safety outcomes and association with recurrence-free survival 132
Totale 18.990
Salva come PNG Salva come JPEG
Categoria #
all - tutte 88.135
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 88.135
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022768 0 0 0 20 18 65 34 42 74 137 123 255
2022/20231.326 106 86 212 113 58 235 42 67 92 56 219 40
2023/20241.661 63 62 152 61 49 393 551 62 44 24 38 162
2024/20254.287 121 148 319 234 459 278 139 175 479 323 455 1.157
2025/202612.280 790 1.430 1.420 1.350 2.273 396 1.221 468 399 732 622 1.179
2026/20271.897 651 396 807 43 0 0 0 0 0 0 0 0
Totale 26.752